Fenretinide activity in retinoid-resistant oral leukoplakia

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 3109-3114

  Lippman, Scott M ^a   Lee, J Jack ^a   Martin, Jack W ^a   El Naggar, Adel K ^a   Xu, Xiaochun ^a   Shin, Dong M ^b   Thomas, Margaret ^a   Mao, Li ^a   Fritsche Jr , Herbert A ^a   Zhou, Xian ^a   Papadimitrakopoulou, Vassiliki ^a   Khuri, Fadlo R ^b   Tran, Hai ^a   Clayman, Gary L ^a   Hittelman, Walter N ^a   Hong, Waun Ki ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; FENRETINIDE; RETINOID;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; LEUKOPLAKIA; MALE; NICK END LABELING; PATIENT COMPLIANCE; PRIORITY JOURNAL; TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; APOPTOSIS; DNA DAMAGE; DNA NUCLEOTIDYLEXOTRANSFERASE; DRUG RESISTANCE; FEMALE; FENRETINIDE; HUMANS; IN SITU NICK-END LABELING; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; RETINOIDS; TREATMENT OUTCOME;

EID: 33744784545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2636     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics 2005. CA Cancer J Clin 2005;55:10-30.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328: 184-94.
3. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al Treatment and prevention of intraepithelial neoplasia an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
4. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer (editorial). N Engl J Med 2001;344: 1323-6.
5. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-10.
6. Mayne ST, Lippman SM. Retinoids, carotenoids, and micronutrients. 7th ed. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins: 2005. p. 521-36.
7. Hong WK, Endicott J, Itri LM, et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
8. Hong WK, Lippman SM, Itri L, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
9. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
10. Lippman SM, Lee JJ. Reducing the "risk" of chemoprevention: defining and targeting high risk-2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 2006;66:2893-903.
11. Lippman SM, Hong WK. Cancer prevention by delay. Clin Cancer Res 2002;8:305-13.
12. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype in advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90:1545-51.
13. Lotan R, Xu C, Lippman SM, et al. Suppression of retinoic acid receptor p in oral premalignant lesions and its upregulation by isotretinoin. N Engl J Med 1995;332:1405-10.
14. Pergolizzi R, Appierto V, Crosti M, et al. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer 1999;81:829-34.
15. Ozpolat B, Tari AM, Mehta K, Lopez-Berestein G. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma 2004;45: 979-85.
16. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995;87:1655-7.
17. Dmitrovsky E. Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst 2004;96:1264-5.
18. Appierto V, Villani MG, Cavadini E, Lotan R, Vinson C, Formelli F. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ 2004;11:270-9.
19. Kalli KR, Devine KE, Cabot MC, et al. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol 2003;64:1434-43.
20. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl) retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(κ)B(α) kinase and nuclear factor-κB-regulated gene products. Cancer Res 2005;65:9555-65.
21. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59:14-8.
22. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-41.
23. Sheikh MS, Shao ZM, Li XS, et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995;16:2477-86.
24. Oridate N, Lotan D, Xu XC, Hong WK, Lotan R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 1996;2:855-63.
25. MacCrehan WA. NIST measurements of (4-hydroxyphenyl)retinamide in serum. Clin Chem 1987; 33:1585-92.
26. Sabichi AL, Modiano MR, Lee JJ, et al. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res 2003;9: 2400-5.
27. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:22441-6.
28. Soria JC, Moon C, Wang L, et al. Effects of N-(4-hydroxyphenyl) retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 2001;93:1257-63.
29. Kyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res 1999;59:5917-21.
30. Xu H, Cheepala S, McCauley E, et al. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor independent tumor suppression. Clin Cancer Res 2006;12:969-79.
31. Sun SY, Yue P, Kelloff GJ, et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)-retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomark Prev 2001;10:595-601.
32. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-42.
33. Baglietto L, Torrisi R, Arena G, et al. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer. Cancer Detect Prev 2000;24: 369-75.
34. Doose DR, Minn FL, Stellar S, Nayak RK. Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 1992;32:1089-95.
35. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the branchial epithelium. Clin Cancer Res 2000;6:2973-9.
36. Stephensen CB, Gildengorin G. Serum retinol, the acute phase response, and the apparent misclassification of vitamin A status in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2000;72:1170-8.
37. Chiesa F, Tradati N, Grigolato R, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005;115:625-9.
38. Sun SY, Schroeder CP, Yue P, Lotan D, Hong WK, Lotan R. Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4 HPR at clinically relevant concentrations. Cancer Biol Ther 2005;4:407-13.